Perioperative medicine & outcomes
Cardiotoxicity and peri‐operative considerations in immune checkpoint inhibitor and chimeric antigen receptor T‐cell therapy: a narrative review
Study context
- Population
- Patients receiving immune checkpoint inhibitors or chimeric antigen receptor T-cell therapy, with cardiotoxicity
Methodological detailsPubMed, Embase and Google Scholar searched September 2024, no date limits; findings reported narratively
- PubMed, Embase and Google Scholar searched September 2024, no date limits; findings reported narratively
Main finding
As reported in the abstract
- Early diagnosis of cardiotoxicity critical but challenging due to non-specific symptoms
- Diagnostic tools: ECG, cardiac biomarkers, echocardiography, cardiac MRI, endomyocardial biopsy; no single tool definitive
- High-dose corticosteroids first-line for immune checkpoint inhibitor-induced myocarditis, additional immunosuppression for refractory cases
- Standard HF management protocols in cases of HF
- Tocilizumab and corticosteroids for CAR T-cell-induced cytokine release syndrome, with supportive care incl. fluid resuscitation and vasopressors for severe cases
Original publication
Cardiotoxicity and peri‐operative considerations in immune checkpoint inhibitor and chimeric antigen receptor T‐cell therapy: a narrative review. Anaesthesia. Published 8 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →